Page 40 - ESGO - Vulvar cancer - Complete report_fxd2

Table 10. Original studies presenting data in patients treated with neoadjuvant chemoradiation

Authorreference Year N Chemotherapy regimen Radiotherapy re
Moore et al.a,243 1998 LAVC: N = 71
5-FU 1,000 mg/m² infusion d1-4 + CisP 50 mg/m² 2 courses of 23.8
IV d1, given week 1 of each course of radiotherapy days and daily for

Landoni et al.a,244 1996 LAVC: N = 41 5-FU 750 mg/m² infusion d1-5 + MMC 15 mg/m² 54 Gy in 2 course
Recurr.: N = 17 IV d1 given week 1 of each course of radiotherapy treatment break

Montana et al.a,250 2000 LAVC: N = 46 5-FU 1,000 mg/m² infusion d1-4 + CisP 50 mg/m² 2 courses of 23.8
Beriwal et al.242 2013 LAVC: N = 42 IV d1, given week 1 of each course of radiotherapy days and daily for
Lupi et al.a,252 1996 LAVC: N = 24
break

CisP 40 mg/m² d1 (N = 6) and 5-FU 1,000 mg/m² IMRT 46 Gy in

infusion, d1-5 (N = 36). Two cycles, given the first then 1.8 Gy daily

and last week of radiotherapy d, then 1.6 Gy BID

5-FU 750 mg/m² infusion d1-5 + MMC 15 mg/m² 54 Gy in 2 course
IV d1, given for 2 cycles

Gaudineau et al.253 2012 LAVC: N = 22 Carbo AUC 2 weekly during radiotherapy 50 Gy in 2 Gy dai

Scheistroen et al.251 1993 LAVC: N = 20 Bleo 30 mg IV d1, 3, 5 during weeks 1 + 3 of 30-45 Gy in 3 Gy
radiotherapy

Gerszten et al.254 2005 LAVC: N = 18 5-FU 1,000 mg/m² infusion d1-4 + CisP 50 mg/m² 44.6 Gy in 1.6 G
Eifel et al.245 1995 LAVC: N = 12
IV d1, given first and last week of radiotherapy 1.8 Gy daily for 7

1.6 Gy BID for 5

CisP 4 mg/m²/d infusion d1-4 + 5-FU 250 mg/m²/d 40 Gy in 2 Gy dai
infusion d1-4, given weekly for 4 weeks

Whitaker et al.246 1990 LAVC: N = 9 5-FU 750-1,000 mg/m² infusion d1-4 + MMC 10- 25 Gy in 2.5 Gy f
Recurr.: N = 3 12 mg/m² IV d1, week 1 of each course of
radiotherapy

a Radiotherapy given to the vulva, groin and pelvis unless otherwise stated, 5-FU: 5-fluorouracil, AUC: area under the curv
partial response, CR: complete response, d: days, Gy: Gray, IMRT: intensity-modulated radiation therapy, LAVC: locally a
recurrence, ORR: overall response rate, pCR: pathologic complete response, PR: partial response, pts: patients, Recurr: recurr

 VULVAR CANCE
40